Document Detail

A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network.
MedLine Citation:
PMID:  23104124     Owner:  NLM     Status:  Publisher    
Ischemic strokes, intracranial hemorrhages (ICH) and deep venous thromboembolism (DVT) are clinically important events in patients with gliomas. In this multicentre, noninterventional observational study, current data pertaining to frequency, contributing factors and outcomes of vascular events during times of anti-angiogenic therapy with the antibody against vascular endothelial growth factor, bevacizumab (BEV) was collected from the German Glioma Network. Among 3,889 glioma patients, 70 ischemic strokes (1.8 %) and 123 ICH (3.2 %) were recorded. 143 DVT (5.0 %) were recorded in 2,855 patients. Rates of DVT and ICH, but not of ischemic strokes, increased with the World Health Organization (WHO) grade of glioma. In 81 BEV-treated patients, five ischemic strokes (6.2 %), one ICH (1.2 %) and six DVT (7.4 %) were documented. Compared to patients that were not treated with BEV, ischemic stroke rate was significantly higher during treatment with BEV (p < 0.001). The rates of DVT (p = 0.123) or ICH (p = 0.571) in BEV-treated patients did not differ. On cerebral magnetic resonance imaging (MRI), BEV-related ischemic strokes appeared as diffusion-restricted sites next to contrast-enhancing tumor. 67 % of ICH, 61 % of ischemic strokes and 18 % of DVT occurred postoperatively (within 30 days after tumor resection). Outcome after postoperative ICH was significantly worse than after spontaneous ICH (p = 0.008). Ischemic stroke outcomes did not differ between postoperative and spontaneous occurrence (p = 0.401). Rate of pulmonary embolism did not differ significantly between postoperative and spontaneous DVT (p = 0.133). Relatively low rates of ICH and DVT might be partially due to a high proportion of low-grade gliomas in this patient cohort. The finding of a relevant number of symptomatic, therapy-associated intracerebral diffusion restrictions should be controlled in ongoing phase III studies.
C Seidel; B Hentschel; M Simon; O Schnell; O Heese; M Tatagiba; D Krex; T Reithmeier; A Kowoll; M Weller; W Wick
Related Documents :
19238164 - Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients s...
12372884 - Is incidental appendectomy necessary during radical cystectomy?
2219614 - Treatment of primary nocturnal enuresis by oral androgen mesterolone. a clinical and cy...
1638344 - Reconstruction of the lower urinary tract for neurogenic bladder: lessons from the adol...
1124994 - The resultant force on the femoral head in rheumatoid arthritis.
15264734 - The differential flow of epidural local anaesthetic via needle or catheter: a prospecti...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-27
Journal Detail:
Title:  Journal of neurology     Volume:  -     ISSN:  1432-1459     ISO Abbreviation:  J. Neurol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0423161     Medline TA:  J Neurol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Neurooncology, Neurology Clinic and National Centre for Tumour Disease, University of Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Decision making in juvenile myoclonic epilepsy.
Next Document:  Semicircular canal, saccular and utricular function in patients with bilateral vestibulopathy: analy...